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Abstract
Patients with Eisenmenger syndrome form a small percentage of congenital heart disease
patients. The rarity of this syndrome, combined with its complex pathophysiology, account for
the insufficient understanding of the principles underlying its proper treatment. The main
clinical symptoms are: cyanosis due to secondary erythrocytosis, resulting in increased blood
viscosity, iron deficiency anemia (enhanced by unnecessary phlebotomies), blood clotting dis-
turbances, heart failure and serious supraventricular and ventricular arrhythmias. Recent
decades have seen developments in pulmonary hypertension pathophysiology which have led to
the introduction of new groups of drugs: prostacycline analogs (Epoprostenol, Treprostinil,
Beraprost, Illoprost), phosphodiesterase inhibitors (Sildenafil, Tadalafil), endothelin receptor
antagonists (Bosentan, Sitaxantan, Ambrisentan) and nitric oxide. These drugs should be
administered to patients in III–IV NYHA class. Despite successful early results, the therapeu-
tic effect on patients with Eisenmenger syndrome has not been conclusively established. Our
therapeutic efforts should be directed mainly towards preventing complications. As a rule, we
should avoid agents with no established therapeutic efficacy and try to alleviate symptoms
without any additional risk, so as not to disrupt the existing clinical balance. (Cardiol J 2009;
16, 6: 500–506)
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Introduction
In 1897 an Austrian doctor, Viktor Eisen-
menger, described a patient with ventricular sep-
tal defect (VSD) and cyanosis. Sixty years later,
based on pathophysiological analysis, Paul Wood
described this clinical situation as a secondary pul-
monary hypertension with pulmonary vessel resist-
ance exceeding 800 dyn/s/cm–5 and the presence of
inversed or bidirectional flow between heart cham-
bers or great vessels. He also claimed that the site
of communication does not have any pathognomic
significance [1]. Current data points to secondary
pulmonary hypertension developing earlier in VSD
and patent ductus arteriosus (PDA) than in atrial
septal defect (ASD) [2]. Modern diagnosis of sec-
ondary pulmonary hypertension, also known as
Eisenmenger syndrome (ES), can be made if mean
pressure in the pulmonary trunk (hemodynamic
measurement) exceeds 25 mm Hg at rest and
30 mm Hg during exercise [3]. Pulmonary hyper-
tension results from vasoconstriction, pulmonary
artery remodelling and aggravating thrombotic
processes. Increased pulmonary blood flow leads to
endothelial dysfunction of small arteries which trig-
gers secretion of agents stimulating myocyte hyper-
trophy and proliferation, enhancing adherence and
activation of platelets and leukocytes favoring
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immune inflammation as well as activation of coa-
gulation pathways. Endothelial damage disrupts the
balance between vasoconstrictors, such as endothe-
lin 1 and tromboxane A2, and vasodilators, including
nitric oxide, vasoactive intestinal peptide or prostag-
landin A1, favoring vasoconstriction. At an early stage
of the disease, changes in the pulmonary arteries are
functional and reversible, because a systolic compo-
nent prevails. With time, plexiform lesions become
irreversible. Histologic studies allowed for the stag-
ing of hypertension when Heath-Edward grading
was created in 1958, or 20 years later with the in-
troduction of the Rabinovith classification [4, 5].
Eisenmenger syndrome is observed in 5–10%
of patients with congenital heart disease [6, 7]. It is
caused by the following clinical conditions:
— isolated lesions without pulmonary outflow
tract obstructions: ASD, VSD, PDA, anomalous
pulmonary venous connection;
— complex lesions without pulmonary outflow
tract obstruction:
• common atrio-ventricular canal (CAVC),
• ventriculoarterial discordance (dextro-trans-
position of the great arteries) or atrioventri-
cular and ventriculoarterial discordance
(levo-transposition of the great arteries) with
a non-restrictive ventricular septal defect,
• various forms of truncus arteriosus;
— large aortopulmonary connection:
• aortopulmonary window,
• aortopulmonary collaterals in patients with
pulmonary atresia,
• surgically created aortopulmonary connections
(e.g. Potts and Waterson anastomoses) [8].
Pathophysiology and clinical presentation
of secondary pulmonary hypertension
The dynamics of the progression of secondary
pulmonary hypertension depend on the size of the
leak and its location. Pretricuspid shunt, responsi-
ble mainly for volume overload (ASD, anomalous
pulmonary venous connection), is less frequently
a cause of ES than ‘post-tricuspid’ shunts (VSD, PDA)
generating volume and pressure overload. Long-
-term prognosis does not differ between these two
groups of patients [7]. Patients with Down syn-
drome show a particular predilection for pulmonary
hypertension [9]. Dynamic developments in the
field of pediatric cardiac surgery have led to a re-
duction in the incidence of this syndrome in patients
with simple shunt defects, but there are more cas-
es observed in patients with complex defects whose
lives have been substantially prolonged [10].
Clinical presentation of ES affects multiple or-
gans and results from cardiac anatomic anomalies
and post-operative complications, and to the great-
est extent from size and direction of shunt and re-
sultant blood changes: secondary erythrocytosis
and eventual cyanosis. Increased haemoglobin pro-
duction is an adaptive mechanism allowing for ade-
quate tissue oxygenation. Increased hematocrit
leads to higher blood viscosity followed by specific
clinical symptoms, such as headaches, vertigo, par-
esthesias and myalgias. An additional cause of some
of these symptoms is iron deficiency, observed
mainly in patients who have undergone phleboto-
my. Due to lowered count and dysfunction of plate-
lets and disruption of intrinsic pathway (reduction
of activation of II, VII, IX, X, V and von Willebrand
factors), cyanotic patients often exhibit bleeding and
thromboembolic complications, such as stroke, pul-
monary bleeding and large pulmonary vessel throm-
bosis. Increased heme breakdown facilitates
hyperuricemia and eventually joint and kidney
changes related to gout. Gallstones containing cal-
cium bilirubinate may lead to cholecystitis. Kidney
dysfunction is often observed as a result of second-
ary glomerulopathy. These patients are at risk of
developing infective endocarditis, cerebral abscess
and pneumonia. Finally, frequent causes of death
in this population are dangerous ventricular and
supraventricular arrhythmias and progressive heart
failure [9, 11, 12]. Obviously, survival rates in this
group of patients are worse than the average popu-
lation (55% reach 50 years of age) [13], but they are
still significantly better than in patients with idio-
pathic pulmonary hypertension (75% die within
three years of the diagnosis being made) [14].
Complex non-pharmacological care
The traditional, though still valid, approach to
ES focuses on close monitoring of sufferers in highly
specialized reference centers, cohorting adults with
congenital heart disease (CHD) and lifestyle
modifications in addition to adjunct therapies aimed
at maintaining the existing balance of pressures in
pulmonary and systemic circulations, as well as
balance between bleeding and hemostasis.
General recommendations include instructing
patients to abstain from physical exertion that could
lower systemic pressure and enhance right to left shunt
prior to decreased saturation. Besides, high pulmonary
resistance eliminates additional left atrial and ventricu-
lar inflow, which precede a drop in ejection fraction.
Eisenmenger syndrome patients should avoid
dehydration (i.e. diarrhea, vomiting, heat, fever)
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facilitating an increase in blood viscosity and final-
ly thrombotic complications. With adequate hydra-
tion, an air filter must be used to avoid air embo-
lism if an intravenous line is in place [2, 11].
Non-cardiac necessary interventions should be
performed in centers providing adequate anesthesia.
Non-cardiac surgery is one of the commonest caus-
es of death in this population. Most anesthetics lead
to systemic drop in blood pressure and resultant
aggravation of right to left shunt and desaturation.
On the other hand, a sudden rise in resistance may
lead to right ventricular failure. Intraoperative ar-
rhythmias, significant blood loss and bleeding com-
plications are typical of cyanosis. For that reason, lo-
cal anethesia is preferred. However, epidural anesthe-
sia is related with greater hypotensive effect and the
risk of bleeding and is not superior than general an-
esthesia. It is important to carry out intraoperative
monitoring of volemia and pressure changes as well
as pulse oximetry to assess oxygen saturation [4, 8].
General practice is to apply phlebotomy which
is allowed only in coexistent symptoms of exces-
sive viscosity observed with hematocrit exceeding
65%. A serious side effect of these procedures is
iron deficiency anemia resulting in microcytosis
aggravating thrombotic complications. It is fre-
quently missed, as the hemoglobin may be less then
15 g/dL, but should be greater then 18 g/dL [11].
Contrary to previous beliefs, increased hematocrit
does not lead to dangerous strokes and its risk fac-
tors are low levels of iron, hypertension and atrial
fibrillation [15]. Phlebotomy may be also applied
before the planned surgical intervention to improve
hemostasis. One phlebotomy cannot exceed 250–
–500 mL, at the same time replenishing with 750–
–1000 mL of IV saline. No more then four phlebot-
omies should be performed during one year. If this
does not bring about clinical improvement, iron
deficiency anemia must be suspected, and oral low
dose of ferrous sultate (325 mg/d.) administered.
The question of antithrombotic therapy re-
mains unanswered. Due to both thrombotic and
bleeding risk in these patients, treatment with cou-
marin derivatives is accepted only in atrial fibrilla-
tion, intracardiac mechanical prostheses and con-
duits with advanced heart failure. An indication for
such treatment are episodes of massive pulmonary
thrombosis, seen in about 30% of patients with ES,
although a great expert on the topic, Josef Perloff,
is against the administration of coumarin derivatives
even in such circumstances. He maintains that an-
tithrombotic agents may lead to usually intractable
pulmonary hemorrhage [16, 17]. Hemoptysis is
a frequent clinical complication which can be life-
threatening and may require an adequate therapeu-
tic approach including hospitalization, restricting
physical activity and cough reflex elimination. Bron-
choscopy is contraindicated as a potential source of
pulmonary hemorrhage. If no clinical improvement
ensues, platelet mass, fresh frozen plasma, fac-
tor VIII, vitamin K or cryoprecipitate should be ad-
ministered [11].
A high risk of serious pulmonary infections ne-
cessitates flu and anti-pneumococci vaccination [9].
Oxygen administration does not usually lead to
increased saturation, but can bring about dry air-
ways [18].
There are no evidence-based recommenda-
tions for arrhythmias and heart failure in patients
with secondary pulmonary hypertension. Serious
supraventricular arrhythmias require emergency
cardioversion to restore sinus rhythm. Due to the
high risk of clinical deterioration in patients with
ES, no preliminary prolonged antithrombotic ther-
apy is required [19]. Chronic pharmacotherapy of
arrhythmias should exclude negative inotropic
agents. Heart failure treatment in this population
is also based on theoretical pathophysiological as-
sumptions. Diuretic use must be moderate, so as
not to cause increased hematocrit or a drop in car-
diac output. Vasodilator administration is limited
due to the danger of decreased systemic pressure
and enhanced right to left shunt followed by desat-
uration [20]. A small retrospective study focusing
on angiotensin-converting enzyme (ACE) inhibitors
used by ten cyanotic patients showed improve-
ments in physical endurance in those patients with
no adverse effects on blood pressure or oxygen sat-
uration, despite the afterload reducing agent. It was
postulated that improvement of cardiac output on
ACE inhibitors offsets the potential for worsening
of right to left shunting in those patients [21].
Pregnancy is strongly contraindicated in these
patients because of very high mortality among preg-
nant women [22]. Gravidas with pulmonary hyper-
tension, high pulmonary resistance compounded
with increased volemia may lead to right ventricu-
lar failure. At the same time, diminished ‘return’ to
the left ventricle leads to decreased cardiac output.
Extreme cases may feature syncope or even death
resulting from coronary or central neural system
ischemia. Pregnancy-related drop in systemic pres-
sure enhances right to left shunt, augmenting cya-
nosis and causing often life-threatening hypoxemia
[9]. An additional factor contributing to a higher risk
of life-threatening complications in cyanosis is sus-
ceptibility to thromboembolic complications, bleed-
ing and the risk of pulmonary artery rupture [23].
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Most sudden deaths and irreversible hypoxia relat-
ed deaths are seen within the first ten days of de-
livery [24]. The risk of death in idiopathic hyper-
tension is 30%, and reaches 50% in secondary pul-
monary hypertension. This gloomy statistic, despite
the substantial medical progress made, has not
changed over the last few decades [25]. Secondary
pulmonary hypertension poses significant risk for the
fetus, even if pulmonary pressure does not exceed
half of the systemic values [22]. Patients with this
diagnosis should be strongly discouraged from be-
coming pregnant. Due to substantial risk to the moth-
er’s health, pulmonary hypertension is an indication
for early termination of pregnancy. If a woman de-
cides to continue pregnancy, bed rest is necessary
as well as treatment of right ventricular failure. An-
tithrombotic therapy, oxygen, prostacyclins and ni-
tric oxide can all be implemented, even though there
is no evidence supporting this approach [26]. Con-
traception is recommended, taking into account es-
trogen-related risk of thrombotic complications and
progesterone-related increase in volemia [27].
The ultimate therapy in this group of patients
is lung or heart-lung transplantation. The decision
to transplant should be made after deep considera-
tion. The procedure should be offered to patients
in the advanced stages of the disease because of the
long term good clinical status of ES patients com-
pared to patients with pulmonary hypertension re-
lated to other conditions. The analysis of survival
rate of 605 heart-lung or lung transplants of end
stage ES patients shows that recipients are not
a homogeneous group. Patients with ventricular
septal defect have a better prognosis than those
with ASD or persistent ductus arteriosus [28]. Lung
transplant should be accompanied by anatomical
correction of the defect. It should be remembered
that patients with pulmonary hypertension due to
cardiac defect associated with shunt have the high-
est perioperative mortality amongst all subjects of
heart-lung transplants [29].
Finally, the importance of professional psycho-
logical help to ES patients must be underscored.
Living with activity-limiting chronic illness and vis-
ible cyanosis may be a great hurdle for some young
people [30].
Pharmacological approach
The last decades have seen much progress
in the study of pathophysiology of pulmonary
hypertension,n which has resulted in the introduc-
tion of new groups of agents for the treatment of
this condition: prostacycline derivatives, phosphodi-
esterase inhibitors, endothelin receptor antagonists
or nitric oxide. These drugs should be administered
to patients in New York Heart Association (NYHA)
functional class III and IV [9]. Their therapeutic
effect in ES patients has not been fully document-
ed. Due to intracardiac shunt, agents effective in
pulmonary hypertension related to other causes can
produce varying results. Pulmonary pressure low-
ering drug can usually decrease systemic pressure.
This situation may lead to an increased right to left
shunt, followed by decreased blood saturation and
decreased cardiac output. It is necessary to evalu-
ate clinical efficacy of the drug in the separate group
of patients. Such evaluation is unfortunately very
difficult due to the small number of patients and
relatively low mortality in this group. Therefore, the
primary end points of the studies are characteristics
related to patients’ clinical status, such as six-minute
walk test, ventricular function or natriuretic hor-
mones. There are only a few randomized trials in the
therapy of pulmonary hypertension which involved
patients with CHD and they did not form a separate
group eligible for adequate analysis [31–36].
The best studied group of drugs lowering pul-
monary pressure are prostacyclin derivatives. Their
vasodilator effect, resulting from adenyl cyclase
activation leading to increased intracellular adeno-
sine monophosphate, is accompanied by antiprolif-
erative and antiplatelet effects which are responsi-
ble for the agent’s efficacy in spite of impaired va-
sodilation [37]. Epoprostenol is administered IV due
to its short half-time (3–5 min). It has the strong-
est effect of all known agents. It has a documented
positive impact in CHD patients improving effort
tolerance and saturation [38, 39]. Venous cannula-
tion poses a threat of infection and thromboembo-
lism but these complications are not more frequent
in ES than idiopathic hypertension [40, 41]. Thera-
peutic effects of Epoprostenol, recognized as im-
proved cardiac function, are also comparable [35, 36,
38]. Search for new improved ways of administra-
tion led to the introduction of Treprostinil admin-
istered subcutaneously just like insulin prepara-
tions with microinjection pump (half-time of 30–80
min). Simmoneau et al. [31] have proved its effica-
cy in a randomized, multi-center trial including 469
patients with different etiologies of pulmonary hy-
pertension. One hundred and nine patients repre-
sented Eisenmenger syndrome, six-minute walk-
ing test improvements did not differ significantly
from the ones achieved in other pulmonary hyper-
tension patients and was inversely related to base-
line cardiac function parameters. Oral Beraprostem
led to clinical improvements only in patients with
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idiopathic hypertension in a three-month observa-
tion period, with no beneficial effect after one year
[42]. This agent is not currently used in Europe.
Available literature does not include a thorough
analysis of volatile prostanoid Illoprost use in the
analyzed group of patients.
It has been demonstrated that about 30% of
patients with pulmonary hypertension associated
with CHD react with decreased pulmonary resist-
ance after nitric oxide therapy [43]. In spite of con-
stant technological progress, the administration of
this substance is still difficult; there are reports of
effective therapy in women in childbirth who are at
particular risk [44].
Sildenafil, oral inhibitor of 5 phosphodiesterase
enhances vasodilation of nitric oxide by increasing
cGMP concentration and has antiproliferative prop-
erties towards smooth muscles of the vessels [45].
Besides, this drug increases contractility of the
hypertrophic right ventricle [46]. One large rand-
omized trial SUPER-1 (Sildenafil Use in Pulmonary
arterial hypertension) [47] and two smaller trials
[36, 48] established the safety profile of the agent
and short-term efficacy manifested as improved
effort tolerance in patients with all sorts of pulmo-
nary hypertension. These studies included patients
with Eisenmenger syndrome but their data was not
analyzed separately. Improved cardiac function af-
ter Sildenafil was observed in a few other studies
which analyzed three, seven and 20 cases of sec-
ondary pulmonary hypertension respectively [49–
–51]. Sastry et al. [52] proved that efficacy of four
months of Sildenafil in the group including 90% of
ES patients is comparable to the one observed in
the SUPER-1 study. Short-term analysis proved the
efficacy of another phosphodiesterase inhibitor:
Tadalafil in 16 patients with ES [53]. Available stud-
ies show good safety profile of both preparations.
Endothelin receptor antagonists (ETA and
ETB) have good efficacy records in pulmonary hy-
pertension. Hormone levels have been elevated in
Eisenmenger syndrome patients [54] and that pro-
vided the basis for the use of this group of drugs.
Bosentan is an oral ETA and ETB receptor blocker
which lowers the pressure and pulmonary vascular
resistance, decreases fibrotic and inflammatory
changes of the vessels, including long-term obser-
vation, which was confirmed during controlled clin-
ical trials of patients with varied underlying patho-
physiological causes [32, 55]. A few open-label un-
controlled studies showed efficacy of this agent in
patients with ES confirming clinical improvements
including effort tolerance and hemodynamic pa-
rameters of the pulmonary circulation [56, 57].
Long-term positive effects of Bosentan have also
been reported [58, 59]. BREATH 5 (Bosentan Ran-
domised Trial of Endothelin Antagonist Therapy)
was the first large, randomized, multi-center trial
designed and carried out according to the rules of
evidence based medicine. It included 56 patients
and lasted for 16 months. It confirmed decreased
resistance and pulmonary pressure and an increase
in cardiac output measured with six-minute walk-
ing test, with no changes in blood saturation [60].
What’s more, there were no reported imbalances
between pulmonary and systemic circulation, which
make this drug one of the most promising agents
in ES patients. Good response to the drug was re-
ported in all participating patients with ES after
24 consecutive weeks of observation [61]. The long
term efficacy has been questioned by van Loon et
al. [62] for Bosentan in this group of patients. Two
controlled, randomized trials (STRIDE 1 and
STRIDE 2) dealt with selective endothelin recep-
tor antagonist: Sitaxantan. Quite large study groups
of 178 and 247 patients, among them ES patients
who did not form a separate group undergoing dis-
tinct analysis, confirmed the efficacy and safety of
the administered agent [34, 36, 47].
Good results with Bosentan and Epoprostenol
prompted researchers to combine both therapies.
But this did not produce any better therapeutic re-
sults [63–65]. Lack of data on this sort of treatment
in patients with ES resulted in the lack of indica-
tions for it.
Recent years have seen the arrival of a new
selective ETA receptor antagonist called Ambrisen-
tan. It requires more clinical investigation and its
efficacy is evaluated in the ARIES (Ambrisantan in
Patients with Moderate to Severe Pulmonary Ar-
terial Hypertension) study [66]. This new arrival
into pharmaceutical market made Faber [67] thor-
oughly review currently available pharmacological
strategies. Meta-analysis of 16 trials conducted in
2005 showed that the treatment improved physical
endurance, yet did not improve mortality in patients
with pulmonary hypertension [68]. The only excep-
tion turned out to be epoprostenol [40]. Another
point is the fact that even though most clinical tri-
als of drugs in pulmonary hypertension focus on
comparing results of an imprecise six-minute walk-
ing test; the most significant improvements in the
latter parameter were achieved after rational reha-
bilitation [69]. Although both the patient and phy-
sician aim at clinical improvement, only small
changes are achieved despite varied therapies used.
It seems that we are still at the beginning of the
path. Constant research into the molecular basis of
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the pathology of this condition is focusing on inflam-
matory and proliferative processes. This seems
reasonable taking into account the past use of three
paths of modulation of vessel wall resistance [70].
New light can be shed on the pathophysiology of
pulmonary hypertension through analysis of right
ventricular function, with the expansion of echocar-
diography and magnetic resonance and the imple-
mentation of specific biomarkers for the cardiac
function evaluation. The objectivity of drug stud-
ies would be enhanced with a change of end points
into a single one: patients’ death, despite metho-
dological problems (small groups, relatively low
short-term mortality). Such planning requires mul-
ti-center co-operation and marked prolongation of
studies [67]. Examples of contradictory conclusions
were the results of the study on oral beraprost,
which showed a significant improvement in
a three-month randomized controlled trial, but failed
to show sustained benefit in a subsequent long-term
observation [42].
Summary
Studies of targeted pharmacological therapy for
pulmonary hypertension, especially of patients with
Eisenmenger syndrome, have been conducted for
little more than a decade. Despite certain methodo-
logical inaccuracies, we may hope for their dynamic
developments. While waiting for an effective thera-
peutic agent, we can provide patients with rational
care. Our therapeutic efforts should concentrate on
preventing complications. We should avoid drugs
with no established therapeutic efficacy record, and
try to alleviate symptoms without any additional risk,
so as not to disrupt the existing clinical balance.
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